Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
Breast Cancer Research and Treatment|February 12, 2024
The impact of germline BRCA pathogenic variants in locally advanced, triple negative breast cancer treated with platinum-based neoadjuvant chemotherapyRaz Mutai, Iryna Kuchuk, Alexandra Goldshtein, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|August 29, 2025
TLD: An optimized liposomal doxorubicin formulation with small vesicle size for improved anti-tumor efficacySime Brkic, Silvia Erni, Younes Louaguenouni, et al.
Cancer Chemotherapy and Pharmacology|July 8, 2022
Ex-vivo activation of a liposomal prodrug of mitomycin C by human tumorsShira Dorot, James Tankel, Victoria Doviner, et al.
Endocrine-Related Cancer|May 27, 2006
The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-RDavid J Gross, Gabriel Munter, Menachem Bitan, et al.
Pharmaceutics|November 25, 2023
Harnessing Nanomedicine to Potentiate the Chemo-Immunotherapeutic Effects of Doxorubicin and Alendronate Co-Encapsulated in Pegylated LiposomesAlberto Gabizon, Hilary Shmeeda, Benjamin Draper, et al.
Anti-Cancer Drugs|June 1, 2017
Dexrazoxane added to doxorubicin-based adjuvant chemotherapy of breast cancer: a retrospective cohort study with a comparative analysis of toxicity and survivalEsther Tahover, Amiel Segal, Rut Isacson, et al.
The Oncologist|May 25, 2012
Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences?Maryann Kwa, Robert Baumgartner, Linda Shavit, et al.
Cancer Research|February 21, 2013
Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncologyUma Prabhakar, Hiroshi Maeda, Rakesh K Jain, et al.
Dalton Transactions (Cambridge, England : 2003)|May 26, 2018
Manganese-52: applications in cell radiolabelling and liposomal nanomedicine PET imaging using oxine (8-hydroxyquinoline) as an ionophorePeter Gawne, Francis Man, Jesper Fonslet, et al.
Journal of the National Cancer Institute|October 9, 2014
Words matter: distinguishing "personalized medicine" and "biologically personalized therapeutics"Nathan I Cherny, Elisabeth G E de Vries, Linda Emanuel, et al.
Pageof 6